Beyond the Hype: How Biotech Startups Manage Risk for Real-World Drug Development

Biotech’s Bright Spots: Case Studies in Resilient Drug Discovery Innovation

There are over 5,800 biotech startups eager to innovate and find solutions to complex human issues. Each has to walk the line of building a team of capable experts, performing thorough research and development (R&D), undergoing FDA approvals, and offering clinical trials. At the end of the day, only a few successful ones are capable of delivering worthwhile drug discovery to the market. Let’s look at five promising startups ticking these boxes so far.

Nabla Bio

Antibodies have been a long-standing area of study in biotechnology, as they’re the crux of helping prevent diseases. They’re also notoriously hard to develop, with only about three attempts effectively targeting disease-controlling proteins, called multipass membrane proteins, so far. That is, until Nabla Bio entered the picture.

This startup, founded in 2020, employs generative AI to design antibodies that tackle previously inaccessible protein targets. Recently, Nabla released a study successfully proving that their AI-driven platform can design many therapeutic antibodies from scratch, breaking the barriers of time and extensive research to develop key disease prevention solutions.

Although the company has already raised $37 million in Series A funding, its deals with pharma giants like AstraZeneca and Bristol Myers Squibb for over $500 million are helping advance its protein drug development capabilities to materialize its designs.

ALZpath

ALZpath is a California startup founded in 2020 taking early Alzheimer’s diagnosis into its own hands. Although this degenerative brain condition is known for its subtle early symptoms that are difficult to spot, the startup is making waves by developing the first commercial test that can accurately detect the ptau217 biomarker in blood. Previously, doctors could only diagnose the disease through cognitive tests, costly PET scans, and cerebrospinal fluid tests.

This game-changer in Alzheimer’s early diagnosis and subsequent preventive health caught the attention of Big Pharma names like Roche, which licensed ALZpath’s antibody and partnered with Eli Lilly to gain FDA approval in 2024. Neurocode was also the first US laboratory to make the ALZpath test available for clinical diagnostic use, clinical trials, and other research purposes.

The startup’s advancements have been so critical that Time Magazine named it one of 2024’s Best Inventions, further cementing the company’s momentum to positively impact Alzheimer’s.

Viome

One of the wonders of tech advancement is being able to personalize experiences on all levels—something AI has helped further. In biotech, this translates into delivering tailored health solutions because everyone’s body is different. Viome, a microbiome startup founded in 2016 by serial entrepreneur Naveen Jain, uses AI to study people’s microbiomes and provide supplements and other suggestions that can prevent diseases, and improve gut health and overall well-being.

The company has developed an at-home test kit that people can order and self-administer à la 23andMe to receive their personalized microbiome study alongside solutions with preventive purposes, selling over 500,000 to date.

What’s more, Viome has proven its worth and validity by overcoming regulatory challenges that previous competitors like uBiome weren’t able to surpass, resulting in defrauding investors with an imperfect product. Its innovative approach to health improvement has landed it deals with CVS and, more recently, Microsoft, becoming a commercial success and putting its vital data to work by partnering with tech leaders.

Candid Therapeutics

In the highly competitive autoimmune solutions landscape, it’s critical to make a big first impression. Candid Therapeutics is doing just that, launching in September 2024 with an investment of $370 million and strategically acquiring two biotech companies right off the bat. The company aims to be the first to develop T-cell engager antibodies that deplete specific B-cell populations by targeting autoimmune genetic diseases, more specifically in the oncology space.

Its acquisitions of Vignette Bio and TRC 2004 gave Candid their lead assets, CND106 and CND261, which are crucial for the development of T-cells. This initial move accelerated the startup’s pipeline, allowing it to focus on filing an Investigational New Drug (IND) Application with the FDA to begin autoimmune disease testing. It expects to have data on the assets’ safety by the end of 2025.

Although not every company can afford to follow in Candid’s steps of rapid early development, its strategic planning and execution have also managed to set it far apart and ahead of its competitors.

Benchling

Who’s helping the scientists and entrepreneurs perform biotechnology research with more efficiency? That’s Benchling’s job. This Y Combinator success, founded in 2012 by MIT students, brings a cloud platform to those who need it—biotech companies, academic institutions, and other startups—to assist in R&D efforts like data management, experimental design, biomolecule tracking, and workflow automation.

In 2022, its founders told Y Combinator that no software investors but one were keen on biotech: Paul Graham. Meeting him prompted them to apply to the incubator and further develop their platform to offer a freemium model that drove early adoption and community building.

Today, the company is used by over 200,000 scientists across more than one thousand companies and 7,500 academic and research institutions. And it’s all thanks to Benchling’s complete solution, which allows scientists to move from legacy systems to a cloud platform that lets them oversee every R&D stage, from experimental planning to bioprocess development and in vivo studies.

The Pillars of Biotech Startup Success in Today’s Market

Biotech’s premise is looking for solutions where no one else has in the past, innovating at higher levels beyond any other industry. But it’s not a matter of luck or fate—every startup at the top has carefully carved its path with a knowledgeable team, the right technological approach, and meticulous planning.

The Foundational Elements of a Biotech Companies

Some initial winning elements include having a strong scientific foundation and vision. This means backing your solution with groundbreaking research and validated technology—for many, this is where a startup idea comes from.

A clear and compelling vision with real-world impacts on unmet medical needs, such as ALZpath’s innovative quest for early Alzheimer’s detection, propels concepts from ideas to action.

Having a well-balanced team is also crucial to help secure success. For instance, scientists must be supported by business-oriented leaders who can materialize their ideas.

Partnering with an experienced founder and advisory board will equip a startup with industry knowledge that goes beyond a brilliant idea; these decision-makers will lend their strategic vision in areas like talent acquisition and retention, fundraising, capital allocation, and more (this is especially handy in competitive hubs like San Francisco).

The Importance of Financial Planning and Partnerships

Then it’s time to talk about money. Considering diverse funding sources, from fundraising to leasing and making partnerships, will help fund the business from many fronts without losing equity and decision-making control.

Biotech can be very demanding, requiring teams to craft long-term financial plans that sustain many R&D cycles, stretch cash flow, and manage burn rates. As such, biotech companies are in this sector for the long haul, thinking less about revenue generation and more about strategic investment and milestone achievement for future valuation.

Making partnerships also makes an impact on gaining initial momentum and leveraging early funding rounds. In biotech, academia and the private sector often come together to maximize capital and knowledge, lifting each other up in the name of scientific and commercial advancements. Pharma companies often scoop up startups as well to boost their innovative ideas with capital and resources. An idea, joining industry clusters like the Bay Area can help find the right partners.

Handling Regulatory and IP Requirements

Entrenching regulatory practices in a startup’s core from the onset is crucial to secure its success, especially when regulators often clip startups’ wings if their technologies come up short.

For instance, running an efficient clinical trial design from the start and executing it to a T will minimize issues down the line. Familiarizing the startup with regulations and proactively engaging with regulatory bodies early on will also help reduce the risk of approval obstacles and extended pipelines.

Moreover, building a proper IP strategy will save founders headaches like copyright infringement and slow patent processes. Thus, establishing early and broad patent protection and a global IP filing strategy are paramount in biotech.

Embracing New Technologies in Life Sciences

While it may seem obvious, we must highlight the importance of integrating emerging technologies in biotechnology. AI and machine learning have brought about advancements that couldn’t have been made otherwise, such as Nabla Bio’s AI-driven antibody creation platform.

Investing in technologies that make data management and analytics easier is also worthwhile when it comes to such a technical industry, marked by Benchling’s success in that area.

Navigating the Minefield: Core Risks and Mitigation Strategies for Biotech Startups

Biotech is a high-stakes industry with vast rewards for those who play their cards right. Risks, as always, are prevalent, and success hinges on knowing how to mitigate them effectively.

Scientific and Technical Risks

Avoid obstacles like preclinical and clinical trial failures and reproducibility issues by doing rigorous scientific validation, diversifying the development pipeline, running early proof-of-concept studies, and establishing strong scientific advisory boards.

Regulatory and Compliance Risks

Many startups’ dreams end when it’s time to adhere to regulations and seek approval, creating issues like delays and non-approvals from shifting guidelines and industry watchdogs. To mitigate these risks, seek deep regulatory expertise from the start, set robust Quality Management Systems (QMS), and establish continuous regulatory monitoring.

Financial and Funding Risks

Biotechs aren’t always high-growth and immediate reward generators; instead, they need capital that can last through the long R&D and approval timelines. This is why some of the biggest risks involve capital shortage, valuation challenges, and difficulties securing subsequent rounds. To reduce these salient issues, founders need strategic fundraising, strong investor relations, and realistic financial projections.

But don’t be discouraged. If your questions have shifted to, “How successful are biotech startups?” The answer is they can be very, very successful. Take Candid Therapeutics as an outstanding example of how partnerships and early investor relations can help boost the road to the top. Today, even investment mogul Warren Buffett is interested in biotech.

Intellectual Property (IP) and Legal Risks

In an industry filled with inventions, IP infringement, patent challenges, and trade secret theft can be huge detractors. As a result, building a comprehensive patent strategy, seeking strong legal counsel, drafting employee agreements, and having robust cybersecurity practices are key mitigating factors.

Operational and Supply Chain Risks

As life sciences companies gain momentum, they may face manufacturing complexities, supply chain disruptions, talent retention issues, lab accidents, and even data breaches. Mitigating these risks takes effort, but it’s not impossible. Some safety measures include optimal operational planning, diversified suppliers, talent management, comprehensive cybersecurity protocols, and strong EHS (Environmental, Health, and Safety) programs.

Market and Commercialization Risks

Commercializing their services and products is a biotech’s final goal, but there might be obstacles along the way. For example, slow market adoption, intense competition, pricing pressures, and a lack of reimbursement. To fend off, startups must perform thorough market analysis, set a clear go-to-market strategy, and set strategic partnerships for market access.

The Role of Insurance and Risk Management: Essential Shield for Innovation

In biotech, risks aren’t a matter of “if” but “when.” As we’ve seen, every step of the way poses as many opportunities as it does threats to a startup, so it’s all about leveraging risk management practices with small gains to advance in the game. As for insurance, it can provide strong advantages on the financial, reputational, and legal fronts whenever risks arise. Here are some tailored solutions for biotech companies to capitalize on:

• Clinical Trial Liability Insurance: Provides coverage for bodily injuries from the testing of medical products on human subjects.
• Products Liability Insurance: Covers claims arising from product defects that cause injury or harm (this is particularly important for life science companies due to the impact of drugs and medical devices).
• Intellectual Property Insurance: Covers legal fees and damages related to IP disputes.
• Cybersecurity Insurance: Protects biotech companies from the financial and legal ramifications of data breaches, service disruption, and other cyber-related incidents.
• Property Insurance: Protects the biotech’s physical assets, such as lab equipment and facilities, in case of damage or loss.
• Directors & Officers (D&O) Liability: Covers directors and officers from personal losses in case they’re sued as a result of serving on a board of directors and officers.
• Key Person Insurance: Provides support when the company loses a key team member.

While these packages cover nearly every corner of a company, they should be paired with proactive risk management strategies, including risk identification, assessment, mitigation, and monitoring. This gives startups a strategic advantage over competitors, making them an attractive target for investors, partners, and clients, and allowing them to focus on drug discovery and development rather than the salient risks of the biotech industry.

A balanced blend of vision, determination, resources, a well-structured team, and disciplined risk management can take a biotech from promising to an industry leader. To get there, it’s key to see risk as a manageable aspect of innovation rather than a deterrent, turning the transformative potential of biotech into a reality that addresses global health challenges.

Insurance Rebuilt, End-to-End

We've supported startups from stealth mode to huge funding rounds.

Get a Custom Quote